Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference

GlobeNewswireDec 9 07:30 ET

Earnings Week Ahead: ORCL, GME, ADBE, COST, AVGO, M and More

Seeking AlphaDec 8 08:01 ET

Anavex Life Sciences Down Over 13%, On Track for Largest Percent Decrease Since January -- Data Talk

Dow JonesDec 5 15:12 ET

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

GlobeNewswireDec 2 07:30 ET

Buy Recommendation for Anavex Life Sciences: Promising Alzheimer's Treatment and Expanding Clinical Pipeline

TipRanksNov 27 06:25 ET

Anavex Submits Marketing Authorization Application to EU Regulator for Blarcamesine to Treat Alzheimer's; Shares Jump Pre-Bell

MT NewswiresNov 26 09:29 ET